JP2024515306A - Ｐ－セレクチンに特異的な二環式ペプチドリガンド - Google Patents

Ｐ－セレクチンに特異的な二環式ペプチドリガンド Download PDF

Info

Publication number
JP2024515306A
JP2024515306A JP2023564219A JP2023564219A JP2024515306A JP 2024515306 A JP2024515306 A JP 2024515306A JP 2023564219 A JP2023564219 A JP 2023564219A JP 2023564219 A JP2023564219 A JP 2023564219A JP 2024515306 A JP2024515306 A JP 2024515306A
Authority
JP
Japan
Prior art keywords
seq
peptide
binding complex
multimeric binding
peptide ligand
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023564219A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024515306A5 (https=
JPWO2022223969A5 (https=
Inventor
マクドネル，ケビン
マッド，ジェマ
スカイナー，マイケル
ワッチャム，ソフィー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BicycleTx Ltd
Original Assignee
BicycleTx Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BicycleTx Ltd filed Critical BicycleTx Ltd
Publication of JP2024515306A publication Critical patent/JP2024515306A/ja
Publication of JP2024515306A5 publication Critical patent/JP2024515306A5/ja
Publication of JPWO2022223969A5 publication Critical patent/JPWO2022223969A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023564219A 2021-04-20 2022-04-20 Ｐ－セレクチンに特異的な二環式ペプチドリガンド Pending JP2024515306A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163177185P 2021-04-20 2021-04-20
US63/177,185 2021-04-20
PCT/GB2022/050995 WO2022223969A1 (en) 2021-04-20 2022-04-20 Bicyclic peptide ligands specific for p-selectin

Publications (3)

Publication Number Publication Date
JP2024515306A true JP2024515306A (ja) 2024-04-08
JP2024515306A5 JP2024515306A5 (https=) 2025-04-28
JPWO2022223969A5 JPWO2022223969A5 (https=) 2025-04-28

Family

ID=81448343

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023564219A Pending JP2024515306A (ja) 2021-04-20 2022-04-20 Ｐ－セレクチンに特異的な二環式ペプチドリガンド

Country Status (5)

Country Link
US (2) US12150998B2 (https=)
EP (1) EP4326743A1 (https=)
JP (1) JP2024515306A (https=)
CN (1) CN117203219A (https=)
WO (1) WO2022223969A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201918557D0 (en) * 2019-12-16 2020-01-29 Bicycle Tx Ltd Bicyclic peptide ligands specific for IL-17
CN117203219A (zh) 2021-04-20 2023-12-08 拜斯科技术开发有限公司 特异性针对p-选择素的双环肽配体
WO2025168211A1 (en) 2023-02-10 2025-08-14 Novo Nordisk A/S P-selectin peptide ligands

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1288222A1 (en) 2001-09-03 2003-03-05 Yamanouchi Europe B.V. Peptidic compounds selectively binding to P-selectin
EP1481683A1 (en) 2003-05-30 2004-12-01 Yamanouchi Pharmaceutical Co. Ltd. P-selectin targeting ligand and compositions thereof
AU2009211253B2 (en) 2008-02-05 2014-11-06 Bicyclerd Limited Methods and compositions
CA2966642C (en) * 2014-11-07 2023-03-28 Northwestern University Ornithine aminotransferase inhibition with gaba analogues for treatment of hepatocellular carcinoma
GB201706477D0 (en) * 2017-04-24 2017-06-07 Bicycle Therapeutics Ltd Modification of polypeptides
WO2018197893A1 (en) 2017-04-27 2018-11-01 Bicycletx Limited Bicyclic peptide ligands and uses thereof
JP2021514953A (ja) * 2018-02-23 2021-06-17 バイスクルテクス・リミテッド 多量体二環式ペプチドリガンド
WO2020084305A1 (en) * 2018-10-23 2020-04-30 Bicycletx Limited Bicyclic peptide ligands and uses thereof
CN117203219A (zh) 2021-04-20 2023-12-08 拜斯科技术开发有限公司 特异性针对p-选择素的双环肽配体

Also Published As

Publication number Publication date
US12150998B2 (en) 2024-11-26
CN117203219A (zh) 2023-12-08
EP4326743A1 (en) 2024-02-28
US20250064950A1 (en) 2025-02-27
WO2022223969A1 (en) 2022-10-27
US20220339289A1 (en) 2022-10-27

Similar Documents

Publication Publication Date Title
JP7682852B2 (ja) ＥｐｈＡ２に特異的な二環式ペプチドリガンド
US12377155B2 (en) Bicyclic peptide ligands specific for PSMA
JP2024023291A (ja) 多量体二環式ペプチドリガンド
CN113543813B (zh) Cd38特异性的双环肽配体
US20220088118A1 (en) Bicyclic peptide ligands specific for caix
US20220133732A1 (en) Bicyclic peptide ligands specific for caix
CA3154672A1 (en) Bicyclic peptide ligand drug conjugates
US20250064950A1 (en) Bicyclic peptide ligands specific for p-selectin
US20220064221A1 (en) Bicyclic peptide ligands specific for integrin alpha-v-beta-3
US20220119488A1 (en) Bicyclic peptide ligands specific for integrin alpha-v-beta-3
US20220024983A1 (en) Bicyclic peptide ligands specific for il-17
US20220008545A1 (en) BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR FAPa
US11904020B2 (en) Bicyclic peptide ligands specific for TREM2
US20230021419A1 (en) Bicyclic peptide ligands specific for il-17
CN117337295A (zh) 特异于trem2的双环肽配体
CN119173526A (zh) 转铁蛋白受体1（TfR1）特异性双环肽配体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250418

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250418

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260414